Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to -$2000.0.

  • Ironwood Pharmaceuticals' Cash from Investing Activities rose 8750.0% to -$2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$35000.0, marking a year-over-year increase of 9919.17%. This contributed to the annual value of -$142000.0 for FY2024, which is 9998.62% up from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Cash from Investing Activities stood at -$2000.0, which was up 8750.0% from -$2000.0 recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $27000.0 during Q4 2022, with a 5-year trough of -$999.5 million in Q2 2023.
  • Its 5-year average for Cash from Investing Activities is -$68.5 million, with a median of -$58000.0 in 2024.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Cash from Investing Activities soared by 12109.38% in 2022 and then plummeted by 113568636.36% in 2023.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Cash from Investing Activities stood at -$128000.0 in 2021, then surged by 121.09% to $27000.0 in 2022, then crashed by 15611.11% to -$4.2 million in 2023, then skyrocketed by 99.62% to -$16000.0 in 2024, then surged by 87.5% to -$2000.0 in 2025.
  • Its Cash from Investing Activities stands at -$2000.0 for Q3 2025, versus -$2000.0 for Q2 2025 and -$31000.0 for Q1 2025.